Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6193364 | 0.94 | CNR1 (0.42) | CNR1CNR2NOTUMAVPR1AMAPK1 | |
| SCHEMBL6192908 | 0.93 | POLB (0.42) | CNR1CNR2NOTUMAVPR1AKMT2A | |
| SCHEMBL6193541 | 0.92 | CYP3A4 (0.38) | CNR1CNR2AVPR1AKMT2AMEN1 | |
| SCHEMBL6193991 | 0.91 | SCD (0.36) | CNR1CNR2KMT2AMEN1MAPK1 | |
| SCHEMBL6193882 | 0.91 | TP53 (0.44) | AVPR1AKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL6192944 | 0.89 | ALDH1A1 (0.41) | KMT2AMEN1MAPK1ALDH1A1TP53 | |
| SCHEMBL6195467 | 0.89 | MC4R (0.37) | CNR1CNR2AVPR1AKMT2AMAPK1 | |
| SCHEMBL6191566 | 0.88 | MAPT (0.47) | KMT2AMEN1MAPK1ALDH1A1NPSR1 | |
| SCHEMBL6192611 | 0.87 | KMT2A (0.41) | NOTUMKMT2AMEN1ALDH1A1 | |
| SCHEMBL6196231 | 0.87 | DRD3 (0.41) | NOTUMKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | claimed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | CNR1 49/4885CNR2 68/4885NOTUM 2403/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | CNR1 34/4885CNR2 37/4885NOTUM 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.